Description

Perrigo Company plc: A Dive Into Its Business Strategy & 5 Factors For Our ‘Buy’ Rating! 

Perrigo’s first quarter 2024 financial results reflect a business in recovery and transition, marked by strategic initiatives aimed at long-term growth despite immediate challenges. The company reported a net sales decrease of 8%, primarily driven by its infant formula business and SKU prioritization actions. Organic net sales declined by 7%, with infant formula alone accounting for a 4.3 percentage point drop. This was further impacted by a decrease in retailer inventory for the US over-the-counter medicines, contributing to a subsequent 3.6 percentage point fall, offset slightly by a 1 percentage point growth from other areas.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!